Published in J Clin Endocrinol Metab on September 26, 2012
System-IGF-1 Pathway and Alzheimer's Disease (SIGAL) | NCT00647478
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: an observational study. BMC Neurol (2014) 0.89
BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 0.86
IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice. PLoS One (2014) 0.85
The relationship between serum insulin-like growth factor I levels and ischemic stroke risk. PLoS One (2014) 0.83
Insulin-like growth factor-1 as a prognostic marker in patients with acute ischemic stroke. PLoS One (2014) 0.82
Does cognitive function increase over time in the healthy elderly? PLoS One (2013) 0.81
The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders. Neurosci Biobehav Rev (2016) 0.81
Amyloid beta-mediated epigenetic alteration of insulin-like growth factor binding protein 3 controls cell survival in Alzheimer's disease. PLoS One (2014) 0.78
Relationships between Personality Traits, Medial Temporal Lobe Atrophy, and White Matter Lesion in Subjects Suffering from Mild Cognitive Impairment. Front Aging Neurosci (2014) 0.78
Association between Cognition and Serum Insulin-Like Growth Factor-1 in Middle-Aged & Older Men: An 8 Year Follow-Up Study. PLoS One (2016) 0.77
Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors. PLoS One (2016) 0.76
Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer's Disease. PLoS One (2016) 0.75
The Ames dwarf mutation attenuates Alzheimer's disease phenotype of APP/PS1 mice. Neurobiol Aging (2016) 0.75
Circulating insulin-like growth factor 1 and insulin-like growth factor binding protein-3 level in Alzheimer's disease: a meta-analysis. Neurol Sci (2016) 0.75
Near-infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer's disease: rationale, design, methods, and first baseline data of the Vogel study. J Neural Transm (Vienna) (2017) 0.75
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Randomized intubation with polyurethane or conical cuffs to prevent pneumonia in ventilated patients. Am J Respir Crit Care Med (2015) 4.74
Relationship between blood pressure and outdoor temperature in a large sample of elderly individuals: the Three-City study. Arch Intern Med (2009) 3.38
Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol (2012) 2.65
A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell (2008) 2.55
Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med (2009) 2.41
Poststroke dementia. Lancet Neurol (2005) 2.41
Brain IGF-1 receptors control mammalian growth and lifespan through a neuroendocrine mechanism. PLoS Biol (2008) 2.35
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis (2010) 2.22
Olfactory discrimination learning increases the survival of adult-born neurons in the olfactory bulb. J Neurosci (2006) 2.16
Effects of antihypertensive therapy on cognitive decline in Alzheimer's disease. Am J Hypertens (2009) 2.15
Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag (2008) 2.13
Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude. J Am Geriatr Soc (2015) 2.04
MORPHIT: an observational study on morphine titration in the postanesthetic care unit in children. Paediatr Anaesth (2013) 1.91
Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings. Clin Infect Dis (2009) 1.88
Effect of influenza vaccination of nursing home staff on mortality of residents: a cluster-randomized trial. J Am Geriatr Soc (2009) 1.87
Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain (2008) 1.84
Phenotype associated with APP duplication in five families. Brain (2006) 1.83
Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J (2008) 1.81
Relationship between blood pressure and depression in the elderly. The Three-City Study. J Hypertens (2008) 1.79
Mutations in SPG11 are frequent in autosomal recessive spastic paraplegia with thin corpus callosum, cognitive decline and lower motor neuron degeneration. Brain (2007) 1.76
Ketoconazole in Cushing's disease: is it worth a try? J Clin Endocrinol Metab (2014) 1.72
Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab (2006) 1.67
Renal function in older hospital patients is more accurately estimated using the Cockcroft-Gault formula than the modification diet in renal disease formula. J Am Geriatr Soc (2009) 1.66
Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis. J Alzheimers Dis (2010) 1.65
Premedication for tracheal intubation: a prospective survey in 75 neonatal and pediatric intensive care units. Crit Care Med (2004) 1.63
Phenotypic spectrum of disorders associated with glycyl-tRNA synthetase mutations. Brain (2005) 1.63
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet J Rare Dis (2014) 1.58
The significance of cortical cerebellar microbleeds and microinfarcts in neurodegenerative and cerebrovascular diseases. A post-mortem 7.0-tesla magnetic resonance study with neuropathological correlates. Cerebrovasc Dis (2015) 1.53
Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J Clin Invest (2006) 1.44
Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology (2009) 1.43
C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain (2013) 1.42
Early postoperative prophylactic noninvasive ventilation after major lung resection in COPD patients: a randomized controlled trial. Intensive Care Med (2013) 1.42
The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. Joint Bone Spine (2011) 1.41
Regulation and function of somatostatin receptors. J Neurochem (2004) 1.40
Exponential growth combined with exponential decline explains lifetime performance evolution in individual and human species. Age (Dordr) (2011) 1.32
Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors. Clin Cancer Res (2008) 1.31
Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease. Neurosci Lett (2002) 1.28
Executive functions deficit in mild cognitive impairment. Cogn Behav Neurol (2007) 1.27
Somatostatinergic systems in brain: networks and functions. Mol Cell Endocrinol (2007) 1.26
Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing: a multicenter diagnostic pacemaker study. J Am Coll Cardiol (2002) 1.22
Obestatin partially affects ghrelin stimulation of food intake and growth hormone secretion in rodents. Endocrinology (2007) 1.22
Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord (2014) 1.21
Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics (2008) 1.21
Balance in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women. J Clin Endocrinol Metab (2003) 1.20
A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A (2006) 1.20
Ultradian rhythmicity of ghrelin secretion in relation with GH, feeding behavior, and sleep-wake patterns in rats. Endocrinology (2002) 1.19
The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. J Alzheimers Dis (2010) 1.19
Subcortical hyperintensities are associated with cognitive decline in patients with mild cognitive impairment. Stroke (2007) 1.18
Firing properties of anatomically identified neurons in the medial septum of anesthetized and unanesthetized restrained rats. J Neurosci (2006) 1.17
C9ORF72 repeat expansions in the frontotemporal dementias spectrum of diseases: a flow-chart for genetic testing. J Alzheimers Dis (2013) 1.16
Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord (2004) 1.15
A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. PLoS Biol (2010) 1.14
Prevalence of small cerebral bleeds in patients with a neurodegenerative dementia: a neuropathological study. J Neurol Sci (2010) 1.13
Women and Men in Sport Performance: The Gender Gap has not Evolved since 1983. J Sports Sci Med (2010) 1.12
A possible role for CSF turnover and choroid plexus in the pathogenesis of late onset Alzheimer's disease. J Alzheimers Dis (2012) 1.10
Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother (2009) 1.10
Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype. J Clin Endocrinol Metab (2010) 1.09
An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist (2011) 1.08
Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Mol Neurodegener (2012) 1.08
Genotype-phenotype correlations in Charcot-Marie-Tooth disease type 2 caused by mitofusin 2 mutations. Arch Neurol (2009) 1.08
Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull (2007) 1.08
Prevalence and determinants of cognitive impairment in chronic heart failure patients. Congest Heart Fail (2007) 1.07
Relationship between orthostatic hypotension and cognitive impairment in the elderly. J Neurol Sci (2010) 1.07
Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir. J Acquir Immune Defic Syndr (2004) 1.06
Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Dement Geriatr Cogn Disord (2007) 1.06
Risk factors for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study. J Am Geriatr Soc (2004) 1.05
Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment. J Antimicrob Chemother (2009) 1.05
Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART. Eur J Clin Pharmacol (2009) 1.04
Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Arch Neurol (2007) 1.04
Early postnatal nutrition determines somatotropic function in mice. Endocrinology (2008) 1.04
The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers. J Alzheimers Dis (2012) 1.03
Systematic analysis of candidate genes for Alzheimer's disease in a French, genome-wide association study. J Alzheimers Dis (2010) 1.03
Association study of the GAB2 gene with the risk of developing Alzheimer's disease. Neurobiol Dis (2008) 1.03
Tau aggregation in the hippocampal formation: an ageing or a pathological process? Exp Gerontol (2002) 1.03
Liver: T2-weighted MR imaging with breath-hold fast-recovery optimized fast spin-echo compared with breath-hold half-Fourier and non-breath-hold respiratory-triggered fast spin-echo pulse sequences. Radiology (2002) 1.03
An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. Br J Clin Pharmacol (2008) 1.01
Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children. Antimicrob Agents Chemother (2006) 1.01
Novel analogs of ghrelin: physiological and clinical implications. Eur J Endocrinol (2004) 1.01
Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study. J Alzheimers Dis (2013) 1.00
Ghrelin and obestatin circadian levels differentiate bingeing-purging from restrictive anorexia nervosa. J Clin Endocrinol Metab (2010) 0.99
Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. Alzheimers Dement (2012) 0.99
Interrelationship between the novel peptide ghrelin and somatostatin/growth hormone-releasing hormone in regulation of pulsatile growth hormone secretion. Endocrinology (2003) 0.99
Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia. Neuropsychopharmacology (2007) 0.98